levodopa has been researched along with omeprazole in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (62.50) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Fedele, E; Galante, A; Giacomini, P; Lunardi, G; Pierantozzi, M; Pietroiusti, A; Sancesario, G; Stanzione, P | 1 |
| Bendsoe, N; Ronquist, G | 1 |
| Alizadeh, M; Arj, A; Bagheri-Lankarani, K; Bahri-Najafi, R; Dehbashi, N; Emami, MH; Esmaeili, A; Fattahi, MR; Geramizadeh, B; Kaviani, MJ; Saberfiroozi, MM; Taghavi, AR | 1 |
2 trial(s) available for levodopa and omeprazole
| Article | Year |
|---|---|
Helicobacter pylori-induced reduction of acute levodopa absorption in Parkinson's disease patients.
Topics: Administration, Oral; Aged; Analysis of Variance; Anti-Bacterial Agents; Anti-Ulcer Agents; Area Under Curve; Biological Availability; Drug Therapy, Combination; Helicobacter Infections; Humans; Intestinal Absorption; Levodopa; Omeprazole; Parkinson Disease; Severity of Illness Index; Treatment Outcome | 2001 |
Does delayed gastric emptying shorten the H pylori eradication period? A double blind clinical trial.
Topics: Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Dopamine Agents; Double-Blind Method; Dyspepsia; Gastric Emptying; Helicobacter Infections; Helicobacter pylori; Humans; Levodopa; Metronidazole; Omeprazole; Peptic Ulcer; Sucrose; Tetracycline; Treatment Outcome | 2006 |
6 other study(ies) available for levodopa and omeprazole
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Inhibition of the L-dopa transport system in human epidermal Langerhans cells by omeprazole and its analogues.
Topics: Adenosine Triphosphatases; Biological Transport, Active; Cells, Cultured; Cytoplasmic Vesicles; Enzyme Inhibitors; Epidermal Cells; Gastric Mucosa; Humans; Hydrogen; Lactic Acid; Langerhans Cells; Levodopa; Omeprazole; Potassium | 2004 |